SLDB Solid Biosciences Inc.
USHealthcareAs of 2026-07-08 16:00
Why SLDB matters now
Solid Biosciences Inc. (SLDB) is a US stock in Healthcare. The latest InvestLog snapshot shows $11.00 with -1.35% on the session and $857.0M in market capitalization; recent performance reads 1-month +37.01% and YTD +47.70%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-56.7M, and EPS of $-0.52. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -26.6%.
The latest indexable market news headline is "Solid Biosciences: The Bull Case Is No Longer Just Duchenne" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $17.00; recent insider activity includes Stone Adam Leo filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.44
P/S
0.00
EV/EBITDA
-1.96
DCF Value
$0.41
FCF Yield
-26.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-74.5%
ROA
-45.3%
ROIC
-49.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-56.7M | $-0.52 |
| Q4 2025 | $0.00 | $-49.8M | $-0.53 |
| FY 2025 | $0.00 | $-174.3M | $-1.99 |
| Q3 2025 | $0.00 | $-45.8M | $-0.48 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$17.00
Target (Median)
$17.00
Target Range
$16.00 - $18.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.43
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.